Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mumps vaccine, live is a live-attenuated viral vaccine used for active immunization against mumps. It contains a weakened strain of the mumps virus, such as the Jeryl Lynn strain, which replicates in the recipient to induce a long-lasting immune response without causing the disease. While most commonly administered as part of the trivalent MMR (measles, mumps, and rubella) vaccine, monovalent formulations are produced by companies like Sinovac (Dalian) Vaccine Technology for use in specific populations, such as junior high school entrants or infants. Beyond its primary use in infectious disease prevention, research has explored its potential as an oncolytic agent in cancers like ovarian cancer due to its ability to induce cell fusion and death in malignant cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mumps vaccine, live.